&lt;p&gt;Long Non-Coding RNA &lt;em&gt;PITPNA-AS1&lt;/em&gt; Accelerates the Progression of Colorectal Cancer Through &lt;em&gt;miR-129-5p&lt;/em&gt;/&lt;em&gt;HMGB1&lt;/em&gt; Axis&lt;/p&gt;

Yuan, Chuanping; Yang, Ling

doi:10.2147/cmar.s267844

Cited by 13 publications

(12 citation statements)

References 21 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our functional analyses demonstrate that miR-129-5p inhibits cell proliferation, cell cycle progression and that it mediates BRAFi response in BRAF mutated melanoma. This is in line with previous in vitro studies reporting that miR-129-5p acts as tumor suppressor in lung cancer [65], gastrointestinal cancer [55,57,66,67], esophageal squamous cell carcinoma [68,69], hepatocellular cancer [70], cervical cancer [71], breast cancer [43,72], and glioblastoma [73].…”

Section: Discussionsupporting

confidence: 91%

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

Gebhardt

Edemir

Groß

et al. 2021

Cancers

View full text Add to dashboard Cite

Many melanomas are associated with activating BRAF mutation. Targeted therapies by inhibitors of BRAF and MEK (BRAFi, MEKi) show marked antitumor response, but become limited by drug resistance. The mechanisms for this are not fully revealed, but include miRNA. Wishing to improve efficacy of BRAFi and knowing that certain miRNAs are linked to resistance to BRAFi, we wanted to focus on miRNAs exclusively associated with response to BRAFi. We found increased expression of miR-129-5p during BRAFi treatment of BRAF- mutant melanoma cells. Parallel to emergence of resistance we observed mir-129-5p expression to become suppressed by BRAF/EZH2 signaling. In functional analyses we revealed that miR-129-5p acts as a tumor suppressor as its overexpression decreased cell proliferation, improved treatment response and reduced viability of BRAFi resistant melanoma cells. By protein expression analyses and luciferase reporter assays we confirmed SOX4 as a direct target of mir-129-5p. Thus, modulation of the miR-129-5p-SOX4 axis could serve as a promising novel strategy to improve response to BRAFi in melanoma.

show abstract

Section: Discussionsupporting

confidence: 91%

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

Gebhardt

Edemir

Groß

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Previously, the prognostic value of PITPNA-AS1 was also reported in colorectal cancer and cervical cancer (12,15). Our study firstly provided clinical evidence that PITPNA-AS1 may be used as a novel biomarker.…”

Section: Discussionsupporting

confidence: 62%

“…We also observed that patients with high PITPNA-AS1 expression exhibited advanced clinical stages, positive metastasis and poor prognosis than those with low PITPNA-AS1 expression. Previously, the prognostic value of PITPNA-AS1 was also reported in colorectal cancer and cervical cancer ( 12 , 15 ). Our study firstly provided clinical evidence that PITPNA-AS1 may be used as a novel biomarker.…”

Section: Discussionmentioning

confidence: 82%

“…However, the sample size is relatively small, large clinical trials are needed to conduct. Recently, PITPNA-AS1 was found for facilitating colorectal cancer cells' proliferation and metastasis through miRNA-129-5p/HMGB1 axis (12). In lung squamous cell carcinoma, PITPNA-AS1 was also observed to boost tumor cells' proliferating and migrating processes via recruiting TAF15 for stabilizing HMGB3 mRNA (10).…”

Section: Discussionmentioning

confidence: 99%

“…3, exhibited a high level in several different types of tumors. In recent years, several researches reported the expression and tumor-related function of PITPNA-AS1 in several tumors, including HCC, lung tumor and colorectal tumor (10)(11)(12). However, the roles and related mechanisms of PITPNA-AS1 in the initiation and progressions of HCC were rarely reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

LncRNA PITPNA-AS1 as a Potential Diagnostic Marker and Therapeutic Target Promotes Hepatocellular Carcinoma Progression via Modulating miR-448/ROCK1 Axis

Wang

Cao

2021

Front. Med.

View full text Add to dashboard Cite

Background: Long non-coding RNAs are critical to hepatocellular carcinoma (HCC) developments. LncRNA PITPNA antisense RNA 1 (PITPNA-AS1) is a new regulator in several tumors. However, the mechanism by which PITPNA-AS1 mediates the tumorigenesis of HCC remains unclear.Methods: RT-qPCR was used to detect the level of PITPNA-AS1 in HCC specimens and cells. The biological functions of PITPNA-AS1 were explored by several functional experiments in vivo and in vitro. The binding relationship among PITPNA-AS1, miR-448 and ROCK1 were studied by Luciferase assay and pull-down assays.Results: We found that PITPNA-AS1 expressions were distinctly upregulated in both HCC specimens and cell lines. High PITPNA-AS1 levels were an unfavorable biomarker for patients with HCC. Functionally, knockdown of PITPNA-AS1 suppressed the proliferation, migration and invasion of HCC cells. Mechanistically, PITPNA-AS1 functioned as competing endogenous RNA to increase ROCK1 expressions via sponging miR-448.Conclusion: The newly identified PITPNA-AS/miR-448/ROCK1 axis promoted the oncogenicity of HCC cells. This novel axis is likely to be a promising HCC therapeutic aim.

show abstract

Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response

Ashrafizadeh

Mohan

Rangappa

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Gastrointestinal (GI) tumors (cancers of the esophagus, gastric, liver, pancreas, colon, and rectum) contribute to a large number of deaths worldwide. STAT3 is an oncogenic transcription factor that promotes the transcription of genes associated with proliferation, antiapoptosis, survival, and metastasis. STAT3 is overactivated in many human malignancies including GI tumors which accelerates tumor progression, metastasis, and drug resistance. Research in recent years demonstrated that noncoding RNAs (ncRNAs) play a major role in the regulation of many signaling pathways including the STAT3 pathway. The major types of endogenous ncRNAs that are being extensively studied in oncology are microRNAs, long noncoding RNAs, and circular RNAs. These ncRNAs can either be tumor‐promoters or tumor‐suppressors and each one of them imparts their activity via different mechanisms. The STAT3 pathway is also tightly modulated by ncRNAs. In this article, we have elaborated on the tumor‐promoting role of STAT3 signaling in GI tumors. Subsequently, we have comprehensively discussed the oncogenic as well as tumor suppressor functions and mechanism of action of ncRNAs that are known to modulate STAT3 signaling in GI cancers.

show abstract

<p>Long Non-Coding RNA <em>PITPNA-AS1</em> Accelerates the Progression of Colorectal Cancer Through <em>miR-129-5p</em>/<em>HMGB1</em> Axis</p>

Cited by 13 publications

References 21 publications

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

LncRNA PITPNA-AS1 as a Potential Diagnostic Marker and Therapeutic Target Promotes Hepatocellular Carcinoma Progression via Modulating miR-448/ROCK1 Axis

Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response

Contact Info

Product

Resources

About